372151-71-8
372151-71-8 structure
- Name: Telavancin
- Chemical Name: telavancin
- CAS Number: 372151-71-8
- Molecular Formula: C80H106Cl2N11O27P
- Molecular Weight: 1755.63000
- Catalog: Signaling Pathways Anti-infection Bacterial
- Create Date: 2018-08-25 15:35:21
- Modify Date: 2025-08-26 17:11:25
-
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria[1].
| Name | telavancin |
|---|---|
| Synonyms | Vancomycin, N3''-[2-(decylamino)ethyl]-29-[[(phosphonomethyl)amino]methyl]- |
| Description | Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity[1]. Telavancin (5 μg/mL) exerts bacteriocidal effect against a MRSA strain (COL) and a VISA strain (HIP5836) at a concentration of 5 µg/mL[1]. |
| In Vivo | Telavancin has been tested in various relevant animal models of infection, namely, bacteremia (40 mg/kg/d; s.c.; twice a day, with 12 h space), endocarditis (30 mg/kg/d; i.v.; twice a day, with 12 h space; 4 d), meningitis, and pneumonia with success[1] Animal Model: MRSA bacteremia model in neutropenic mice[1] Dosage: 40 mg/kg Administration: Subcutaneous injection; twice every day spaced 12 h apart Result: Resulted a significantly higher 14-day survival compared with vancomycin-treated animals. Animal Model: Rabbit model of S. aureus endocarditis[1] Dosage: 30 mg/kg Administration: Intravenous injection; twice every day, spaced 12 h for 4 days Result: Significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative. |
| References |
| Molecular Formula | C80H106Cl2N11O27P |
|---|---|
| Molecular Weight | 1755.63000 |
| Exact Mass | 1753.64000 |
| PSA | 607.90000 |
| LogP | 6.99100 |